vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PennyMac Mortgage Investment Trust (PMT). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $93.6M, roughly 1.8× PennyMac Mortgage Investment Trust). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -13.3%). Over the past eight quarters, PennyMac Mortgage Investment Trust's revenue compounded faster (12.3% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.
ESPR vs PMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $93.6M |
| Net Profit | — | $52.4M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 38.6% |
| Net Margin | — | 56.0% |
| Revenue YoY | 143.7% | -13.3% |
| Net Profit YoY | — | 12.5% |
| EPS (diluted) | $0.32 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $93.6M | ||
| Q3 25 | $87.3M | $99.2M | ||
| Q2 25 | $82.4M | $70.2M | ||
| Q1 25 | $65.0M | $44.5M | ||
| Q4 24 | $69.1M | $107.9M | ||
| Q3 24 | $51.6M | $80.9M | ||
| Q2 24 | $73.8M | $71.2M | ||
| Q1 24 | $137.7M | $74.2M |
| Q4 25 | — | $52.4M | ||
| Q3 25 | $-31.3M | $58.3M | ||
| Q2 25 | $-12.7M | $7.5M | ||
| Q1 25 | $-40.5M | $9.7M | ||
| Q4 24 | — | $46.5M | ||
| Q3 24 | $-29.5M | $41.4M | ||
| Q2 24 | $-61.9M | $25.4M | ||
| Q1 24 | $61.0M | $47.6M |
| Q4 25 | 50.6% | 38.6% | ||
| Q3 25 | -11.4% | 47.4% | ||
| Q2 25 | 8.6% | 24.2% | ||
| Q1 25 | -34.0% | -14.2% | ||
| Q4 24 | -6.4% | 51.1% | ||
| Q3 24 | -31.0% | 32.8% | ||
| Q2 24 | 3.5% | 40.2% | ||
| Q1 24 | 52.5% | 43.6% |
| Q4 25 | — | 56.0% | ||
| Q3 25 | -35.9% | 58.7% | ||
| Q2 25 | -15.4% | 10.7% | ||
| Q1 25 | -62.2% | 21.8% | ||
| Q4 24 | — | 43.1% | ||
| Q3 24 | -57.2% | 51.2% | ||
| Q2 24 | -83.9% | 35.7% | ||
| Q1 24 | 44.3% | 64.2% |
| Q4 25 | $0.32 | $0.49 | ||
| Q3 25 | $-0.16 | $0.55 | ||
| Q2 25 | $-0.06 | $-0.04 | ||
| Q1 25 | $-0.21 | $-0.01 | ||
| Q4 24 | $-0.14 | $0.45 | ||
| Q3 24 | $-0.15 | $0.36 | ||
| Q2 24 | $-0.33 | $0.17 | ||
| Q1 24 | $0.34 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $190.5M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $-302.0M | $1.9B |
| Total Assets | $465.9M | $21.3B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $190.5M | ||
| Q3 25 | $92.4M | $181.0M | ||
| Q2 25 | $86.1M | $108.6M | ||
| Q1 25 | $114.6M | $204.2M | ||
| Q4 24 | $144.8M | $103.2M | ||
| Q3 24 | $144.7M | $102.8M | ||
| Q2 24 | $189.3M | $336.3M | ||
| Q1 24 | $226.6M | $343.3M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $299.0M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $968.4M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $5.1B |
| Q4 25 | $-302.0M | $1.9B | ||
| Q3 25 | $-451.4M | $1.9B | ||
| Q2 25 | $-433.5M | $1.9B | ||
| Q1 25 | $-426.2M | $1.9B | ||
| Q4 24 | $-388.7M | $1.9B | ||
| Q3 24 | $-370.2M | $1.9B | ||
| Q2 24 | $-344.2M | $1.9B | ||
| Q1 24 | $-294.3M | $2.0B |
| Q4 25 | $465.9M | $21.3B | ||
| Q3 25 | $364.0M | $18.5B | ||
| Q2 25 | $347.1M | $16.8B | ||
| Q1 25 | $324.0M | $14.9B | ||
| Q4 24 | $343.8M | $14.4B | ||
| Q3 24 | $314.1M | $13.1B | ||
| Q2 24 | $352.3M | $12.1B | ||
| Q1 24 | $373.1M | $12.3B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 2.70× | ||
| Q2 24 | — | 2.76× | ||
| Q1 24 | — | 2.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-7.2B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | -137.76× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-7.2B | ||
| Q3 25 | $-4.3M | $-1.3B | ||
| Q2 25 | $-31.4M | $-2.0B | ||
| Q1 25 | $-22.6M | $-594.3M | ||
| Q4 24 | $-35.0M | $-2.7B | ||
| Q3 24 | $-35.3M | $-983.8M | ||
| Q2 24 | $-7.2M | $243.8M | ||
| Q1 24 | $53.8M | $-342.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | -137.76× | ||
| Q3 25 | — | -22.26× | ||
| Q2 25 | — | -267.53× | ||
| Q1 25 | — | -61.39× | ||
| Q4 24 | — | -58.08× | ||
| Q3 24 | — | -23.76× | ||
| Q2 24 | — | 9.59× | ||
| Q1 24 | 0.88× | -7.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
